AXL and cancer: To assess the efficacy of pharmacologic inhibition of the AXL pathway on endometrial fibrosis, a selective small molecule inhibitor against AXL, Bemcentinib, which has been used to perform clinical trials for treating cancers (Yule et al, 2018; Bumm et al, 2020), was given by oral administration (80 mg/kg, p.o., MedChemExpress; Holland et al, 2010; Lijnen et al, 2011) in an IUA mouse model.